116 related articles for article (PubMed ID: 12605661)
1. Early and intermediate stage Hodgkin's lymphoma--report from the Swedish National Care Programme.
Molin D; Enblad G; Gustavsson A; Ekman T; Erlanson M; Haapaniemi E; Glimelius B; ;
Eur J Haematol; 2003 Mar; 70(3):172-80. PubMed ID: 12605661
[TBL] [Abstract][Full Text] [Related]
2. Treatment of early and intermediate stages of supradiaphragmatic Hodgkin's disease: the Swedish National Care Programme experience. Swedish Lymphoma Study Group.
Glimelius B; Kälkner M; Enblad G; Gustavsson A; Jakobsson M; Branehög I; Lenner P
Ann Oncol; 1994 Nov; 5(9):809-16. PubMed ID: 7848883
[TBL] [Abstract][Full Text] [Related]
3. Early-stage Hodgkin's disease: long-term results with radiotherapy alone or combined radiotherapy and chemotherapy.
Brusamolino E; Lazzarino M; Orlandi E; Canevari A; Morra E; Castelli G; Alessandrino EP; Pagnucco G; Astori C; Livraghi A
Ann Oncol; 1994; 5 Suppl 2():101-6. PubMed ID: 7515642
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.
Chisesi T; Bellei M; Luminari S; Montanini A; Marcheselli L; Levis A; Gobbi P; Vitolo U; Stelitano C; Pavone V; Merli F; Liberati M; Baldini L; Bordonaro R; Pesce EA; Federico M
J Clin Oncol; 2011 Nov; 29(32):4227-33. PubMed ID: 21990405
[TBL] [Abstract][Full Text] [Related]
5. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial.
Somers R; Carde P; Henry-Amar M; Tarayre M; Thomas J; Hagenbeek A; Monconduit M; de Pauw BE; Breed WP; Verdonck L
J Clin Oncol; 1994 Feb; 12(2):279-87. PubMed ID: 7509381
[TBL] [Abstract][Full Text] [Related]
6. Analysis of long-term results and prognostic factors among 138 patients with advanced Hodgkin's disease treated with the alternating MOPP/ABVD chemotherapy.
Brusamolino E; Orlandi E; Morra E; Castelli G; Pagnucco G; Livraghi A; Astori C; Santagostino A; Lazzarino M; Bernasconi C
Ann Oncol; 1994; 5 Suppl 2():53-7. PubMed ID: 7515648
[TBL] [Abstract][Full Text] [Related]
7. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study.
Weiner MA; Leventhal B; Brecher ML; Marcus RB; Cantor A; Gieser PW; Ternberg JL; Behm FG; Wharam MD; Chauvenet AR
J Clin Oncol; 1997 Aug; 15(8):2769-79. PubMed ID: 9256118
[TBL] [Abstract][Full Text] [Related]
8. Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: the experience of the French Society of Pediatric Oncology.
Oberlin O; Leverger G; Pacquement H; Raquin MA; Chompret A; Habrand JL; Terrier-Lacombe MJ; Bey P; Bertrand Y; Rubie H
J Clin Oncol; 1992 Oct; 10(10):1602-8. PubMed ID: 1383434
[TBL] [Abstract][Full Text] [Related]
9. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
10. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.
Carde P; Hagenbeek A; Hayat M; Monconduit M; Thomas J; Burgers MJ; Noordijk EM; Tanguy A; Meerwaldt JH; Le Fur R
J Clin Oncol; 1993 Nov; 11(11):2258-72. PubMed ID: 7693881
[TBL] [Abstract][Full Text] [Related]
11. Treatment of subdiaphragmatic Hodgkin's disease: long-term results and side effects.
Cutuli B; Petit T; Hoffstetter S; Velten M; Dufour P; Giron C; Lederlin P; Jung GM; Bergerat JP; Maloisel F; Bey P; Oberling F
Oncol Rep; 1998; 5(6):1513-8. PubMed ID: 9769397
[TBL] [Abstract][Full Text] [Related]
12. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987.
Tubiana M; Henry-Amar M; Carde P; Burgers JM; Hayat M; Van der Schueren E; Noordijk EM; Tanguy A; Meerwaldt JH; Thomas J
Blood; 1989 Jan; 73(1):47-56. PubMed ID: 2462943
[TBL] [Abstract][Full Text] [Related]
13. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
14. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B
J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364
[TBL] [Abstract][Full Text] [Related]
15. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
Noordijk EM; Carde P; Dupouy N; Hagenbeek A; Krol AD; Kluin-Nelemans JC; Tirelli U; Monconduit M; Thomas J; Eghbali H; Aleman BM; Bosq J; Vovk M; Verschueren TA; Pény AM; Girinsky T; Raemaekers JM; Henry-Amar M
J Clin Oncol; 2006 Jul; 24(19):3128-35. PubMed ID: 16754934
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Early-Stage Unfavorable Hodgkin Lymphoma: Efficacy and Toxicity of 4 Versus 6 Cycles of ABVD Chemotherapy With Radiation.
Gunther JR; Fanale MA; Reddy JP; Akhtari M; Smith GL; Pinnix CC; Milgrom SA; Yehia ZA; Allen PK; Osborne EM; Mawlawi O; Dabaja BS
Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):110-8. PubMed ID: 27325479
[TBL] [Abstract][Full Text] [Related]
17. Mantle irradiation alone for pathologic stage I and II Hodgkin's disease: long-term follow-up and patterns of failure.
Liao Z; Ha CS; Vlachaki MT; Hagemeister F; Cabanillas F; Hess M; Tucker S; Cox JD
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(4):971-7. PubMed ID: 11429225
[TBL] [Abstract][Full Text] [Related]
18. Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. EORTC Lymphoma Cooperative Group. Groupe Pierre-et-Marie-Curie.
Noordijk EM; Carde P; Mandard AM; Mellink WA; Monconduit M; Eghbali H; Tirelli U; Thomas J; Somers R; Dupouy N
Ann Oncol; 1994; 5 Suppl 2():107-12. PubMed ID: 7515643
[TBL] [Abstract][Full Text] [Related]
19. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results.
Viviani S; Bonadonna G; Santoro A; Bonfante V; Zanini M; Devizzi L; Soncini F; Valagussa P
J Clin Oncol; 1996 May; 14(5):1421-30. PubMed ID: 8622055
[TBL] [Abstract][Full Text] [Related]
20. Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: eight-year update of an Italian prospective randomized study.
Biti GP; Cimino G; Cartoni C; Magrini SM; Anselmo AP; Enrici RM; Bellesi GP; Bosi A; Papa G; Giannarelli D
J Clin Oncol; 1992 Mar; 10(3):378-82. PubMed ID: 1740677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]